SBBP - Strongbridge gains on detailed Phase 3 results for Recorlev in Cushing's syndrome

Strongbridge Biopharma ([[SBBP]] +5.9%) is on the rise in the morning hours after announcing the detailed results from the Phase 3 LOGICS study of Recorlev (levoketoconazole) in patients with endogenous Cushing’s syndrome.Data disclosed in a poster session at the ongoing Annual Meeting of the Endocrine Society (“ENDO”) has shown data after a further evaluation of Recorlev withdrawal in comparison to the continuing treatment with Recorlev indicated by the cortisol therapeutic response.LOGICS trial which met its primary endpoint with statistical significance indicated that 54.5% more patients who were withdrawn to placebo had a loss of mean urinary free cortisol (mUFC) response as compared with those who remained on Recorlev (p = 0.0002).Similarly, at the end of the double-blind randomized-withdrawal ("RW") phase, the key secondary endpoint of mUFC normalization was also statistically significant with 45.5% of those treated with RECORLEV maintaining mUFC normalization in the active arm than the placebo arm (p = 0.0015).Backed

For further details see:

Strongbridge gains on detailed Phase 3 results for Recorlev in Cushing’s syndrome